Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer

Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2019-09, Vol.79 (17), p.4491-4502
Hauptverfasser:	Jain, Aditi, Agostini, Lebaron C, McCarthy, Grace A, Chand, Saswati N, Ramirez, AnnJosette, Nevler, Avinoam, Cozzitorto, Joseph, Schultz, Christopher W, Lowder, Cinthya Yabar, Smith, Kate M, Waddell, Ian D, Raitses-Gurevich, Maria, Stossel, Chani, Gorman, Yulia Glick, Atias, Dikla, Yeo, Charles J, Winter, Jordan M, Olive, Kenneth P, Golan, Talia, Pishvaian, Michael J, Ogilvie, Donald, James, Dominic I, Jordan, Allan M, Brody, Jonathan R
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - pathology Cell Line, Tumor DNA Damage Enzyme Inhibitors - pharmacology Female Gene Silencing Glycoside Hydrolases - antagonists & inhibitors Glycoside Hydrolases - genetics Humans Mice, Nude Molecular Targeted Therapy Oxaliplatin - pharmacology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Recombinational DNA Repair Small Molecule Libraries - pharmacology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!